• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

Research Brief on 1-Cyclopropyl-2-(2-methylpropyl)butane-1,3-dione (CAS: 1862724-21-7) in Chemical Biology and Pharmaceutical Applications

1-Cyclopropyl-2-(2-methylpropyl)butane-1,3-dione (CAS: 1862724-21-7) is a novel diketone compound that has recently garnered attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique cyclopropyl and isobutyl substituents, exhibits promising potential as a scaffold for drug development, particularly in the modulation of enzymatic activity and protein-protein interactions. Recent studies have explored its synthetic pathways, physicochemical properties, and biological activities, positioning it as a candidate for further investigation in therapeutic applications.

The synthesis of 1-Cyclopropyl-2-(2-methylpropyl)butane-1,3-dione has been optimized to achieve high yield and purity, as reported in recent literature. Key steps involve the condensation of cyclopropyl methyl ketone with isobutyryl derivatives under controlled conditions, followed by purification via column chromatography. Advanced spectroscopic techniques, including NMR and mass spectrometry, have confirmed the structural integrity of the compound, with CAS registry number 1862724-21-7 serving as a unique identifier in chemical databases.

Preliminary biological evaluations have revealed that this diketone exhibits inhibitory activity against certain kinases and proteases, which are critical targets in oncology and inflammatory diseases. Molecular docking studies suggest that the cyclopropyl group enhances binding affinity to hydrophobic pockets in enzyme active sites, while the diketone moiety facilitates chelation of metal ions essential for catalytic activity. These findings underscore the compound's potential as a lead structure for the development of enzyme inhibitors.

In addition to its enzymatic modulation, 1-Cyclopropyl-2-(2-methylpropyl)butane-1,3-dione has shown promise in metabolic studies. Recent in vitro assays demonstrated its ability to interfere with lipid metabolism pathways, potentially offering applications in metabolic disorder therapeutics. Researchers have also investigated its stability under physiological conditions, noting its moderate half-life in plasma, which could be optimized through prodrug strategies or formulation advancements.

Future research directions for this compound include structure-activity relationship (SAR) studies to refine its pharmacological profile, as well as in vivo efficacy and toxicity assessments. Collaborative efforts between academic and industrial laboratories are expected to accelerate its translation into preclinical candidates. The integration of computational chemistry and high-throughput screening platforms may further elucidate its mechanism of action and off-target effects.

In conclusion, 1-Cyclopropyl-2-(2-methylpropyl)butane-1,3-dione (CAS: 1862724-21-7) represents a versatile chemical entity with multifaceted applications in drug discovery. Its synthetic accessibility, combined with emerging biological data, positions it as a compelling subject for ongoing research. This brief highlights the need for interdisciplinary collaboration to fully exploit its therapeutic potential and address current challenges in bioavailability and target selectivity.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)